FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function
{{output}}
Chimeric antigen receptor (CAR) T cell therapy faces challenges, such as tumor relapse due to antigen loss and poor CAR T cell expansion in vivo. Optimal tonic signaling (spontaneous CAR signaling) is crucial for CAR T cell fitness and antitumor function, requ... ...
